Nontoxicity endpoints in phase I trial designs for targeted, non-cytotoxic agents

Editorial

Edward L Korn. J Natl Cancer Inst. 2004.

. 2004 Jul 7;96(13):977-8.

doi: 10.1093/jnci/djh208.

No abstract available

Comment on

Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development?
Gelmon KA, Eisenhauer EA, Harris AL, Ratain MJ, Workman P. Gelmon KA, et al. J Natl Cancer Inst. 1999 Aug 4;91(15):1281-7. doi: 10.1093/jnci/91.15.1281. J Natl Cancer Inst. 1999. PMID: 10433616 Review. No abstract available.
Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice.
Parulekar WR, Eisenhauer EA. Parulekar WR, et al. J Natl Cancer Inst. 2004 Jul 7;96(13):990-7. doi: 10.1093/jnci/djh182. J Natl Cancer Inst. 2004. PMID: 15240782 Review.